Trade GlycoMimetics - GLYC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0035 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 0.2358 |
| Open | 0.2397 |
| 1-Year Change | -84.39% |
| Day's Range | 0.2347 - 0.2515 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 29, 2025 | 0.2358 | -0.0241 | -9.27% | 0.2599 | 0.2599 | 0.2271 |
| Apr 28, 2025 | 0.2600 | 0.0096 | 3.83% | 0.2504 | 0.2683 | 0.2503 |
| Apr 25, 2025 | 0.2607 | 0.0059 | 2.32% | 0.2548 | 0.2742 | 0.2436 |
| Apr 24, 2025 | 0.2494 | 0.0045 | 1.84% | 0.2449 | 0.2598 | 0.2391 |
| Apr 23, 2025 | 0.2383 | -0.0314 | -11.64% | 0.2697 | 0.2703 | 0.2346 |
| Apr 22, 2025 | 0.2268 | 0.0071 | 3.23% | 0.2197 | 0.2282 | 0.2197 |
| Apr 21, 2025 | 0.2165 | -0.0057 | -2.57% | 0.2222 | 0.2222 | 0.2096 |
| Apr 17, 2025 | 0.2178 | -0.0073 | -3.24% | 0.2251 | 0.2256 | 0.2096 |
| Apr 16, 2025 | 0.2209 | 0.0012 | 0.55% | 0.2197 | 0.2306 | 0.2102 |
| Apr 15, 2025 | 0.2273 | 0.0076 | 3.46% | 0.2197 | 0.2291 | 0.2155 |
| Apr 14, 2025 | 0.2209 | 0.0177 | 8.71% | 0.2032 | 0.2246 | 0.2020 |
| Apr 11, 2025 | 0.2012 | 0.0116 | 6.12% | 0.1896 | 0.2012 | 0.1807 |
| Apr 10, 2025 | 0.1940 | -0.0007 | -0.36% | 0.1947 | 0.2023 | 0.1782 |
| Apr 9, 2025 | 0.1903 | 0.0177 | 10.25% | 0.1726 | 0.1994 | 0.1696 |
| Apr 8, 2025 | 0.1805 | -0.0041 | -2.22% | 0.1846 | 0.1994 | 0.1766 |
| Apr 7, 2025 | 0.1759 | 0.0063 | 3.71% | 0.1696 | 0.1826 | 0.1696 |
| Apr 4, 2025 | 0.1775 | -0.0032 | -1.77% | 0.1807 | 0.1937 | 0.1716 |
| Apr 3, 2025 | 0.1846 | -0.0100 | -5.14% | 0.1946 | 0.2003 | 0.1806 |
| Apr 2, 2025 | 0.2092 | 0.0146 | 7.50% | 0.1946 | 0.2147 | 0.1943 |
| Apr 1, 2025 | 0.2006 | -0.0040 | -1.96% | 0.2046 | 0.2046 | 0.1996 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
GlycoMimetics Company profile
About GlycoMimetics Inc
GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of novel glycomimetic. Its drug candidates include Uproleselan, GMI-1359, Rivipansel, GMI-1687, and Galectin Antagonists. Its Uproleselan a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), a life-threatening hematologic cancer, and potentially other hematologic cancers. The GMI-1359 targets E-selectin and a chemokine receptor. Its Rivipansel is a glycomimetic drug candidate that act as , a pan-selectin antagonist for treatment of vaso-occlusive crisis. It has designed antagonist of E-selectin, GMI-1687, that is suitable for subcutaneous administration. Galectin Antagonists includes Galectin-3, which is a carbohydrate-binding protein.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, GlycoMimetics Inc revenues decreased 89% to $1.2M. Net loss increased 24% to $63.4M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research & Development Expenses increase of 8% to $45.3M (expense), Interest income decrease of 96% to $20K (income).
Equity composition
Common Stock, $0.001 Par, 100M Auth shares, 17,555,497 issd,. Insiders Owns approx. 10.08%.
| Industry: | Bio Therapeutic Drugs |
9708 Medical Center Drive
ROCKVILLE
MARYLAND 20850
US
News
GME shares price forecast: Third-party price target
Read our GameStop (GME) share price forecast for 2025 and beyond, with insights from third-party analysts and market experts
11:40, 28 April 2025
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com